ELCC 2025 | Professor Lin Wu: Long-Term Benefit and Individualized Dose Reduction Strategies of Domestic Third-Generation EGFR-TKI in EGFR T790M-Mutated NSCLC

ELCC 2025 | Professor Lin Wu: Long-Term Benefit and Individualized Dose Reduction Strategies of Domestic Third-Generation EGFR-TKI in EGFR T790M-Mutated NSCLC

At the 2025 European Lung Cancer Congress (ELCC), the team led by Professor Lin Wu from the Hunan Cancer Hospital, Xiangya Hospital, Central South University, presented long-term follow-up data on ASK120067 (rezivertinib) in patients with locally advanced or metastatic EGFR T790M-mutant non-small cell lung cancer (NSCLC). Oncology Frontier invited Professor Wu to comment on the key findings and clinical implications of the study for our readers.
Blood Science Update|Enhancing Hemophilia A Gene Therapy: Strategic F8 Deletions in AAV8 Vectors

Blood Science Update|Enhancing Hemophilia A Gene Therapy: Strategic F8 Deletions in AAV8 Vectors

Hemophilia A is a chronic bleeding disorder resulting from a deficiency in coagulation factor VIII (F8). Current treatment strategies rely on frequent F8 replacement therapy, which is limited by its short half-life, high cost, and the risk of inhibitor development. Gene therapy using adeno-associated virus serotype 8 (AAV8) has emerged as a promising modality, offering liver-targeted, long-term transgene expression. This article recently published in Blood Science investigates whether targeted deletions adjacent to the furin cleavage site of F8 can enhance the therapeutic efficacy and safety of AAV8-delivered BDDF8 constructs in a murine model of hemophilia A.
EBMT 2025 | Prof. Xiaoxia Hu: Focusing on Comprehensive Leukemia Management and Key Findings from the Ruijin Transplant Team

EBMT 2025 | Prof. Xiaoxia Hu: Focusing on Comprehensive Leukemia Management and Key Findings from the Ruijin Transplant Team

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a cornerstone in the treatment of various hematologic diseases. However, several peri-transplant challenges persist, particularly regarding the optimal timing of transplantation, the role of consolidation therapy, and maintenance strategies. At the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025), the transplant team from Ruijin Hospital, Shanghai JiaoTong University School of Medicine, presented several notable studies. Among them, three studies—B254, B259, and A001—focused on comprehensive leukemia management and transplant integration, drawing significant attention from the clinical community. Hematology Frontier invited Prof. Xiaoxia Hu to provide in-depth commentary on these research findings.
EAU 2025 | Dr. Jeffrey S. Damrauer Shares Insights on Bladder Cancer Classification and Treatment

EAU 2025 | Dr. Jeffrey S. Damrauer Shares Insights on Bladder Cancer Classification and Treatment

Bladder cancer is a biologically heterogeneous disease, and its classification plays a critical role in guiding treatment. However, current bladder cancer classification remains based primarily on clinical-pathological features or staging, with molecular subtyping yet to be standardized. At the 2025 European Association of Urology (EAU) Congress, Dr. Jeffrey S. Damrauer from the UNC Lineberger Comprehensive Cancer Center shared key insights on the response of different bladder cancer types to treatment, the role of neoadjuvant therapy, and the growing possibilities of bladder-sparing strategies.